Novel inhibitor of respiratory syncytial virus (RSV), binding the RSV F glycoprotein and inhibiting membrane fusion

Novel ago-PAM for the metabotropic glutamate receptor subtype 2 (mGluR2)

Novel inhibitor of PDE10A

Novel potent, orally active LTA4H inhibitor

Negaive control for JNJ-42396302

Negative control for JNJ-40068782

Novel Adenosine A 2A /A 1 Antagonist With Efficacy In Preclinical Models of Parkinson's Disease

Novel potent, selective, and systemically active positive allosteric modulator (PAM) of mGlu2-receptors

Histamine H3 receptor antagonist and serotonin reuptake inhibitor

Selective androgen receptor modulator with minimal prostate hypertrophic activity stimulating sexual behavior in female rats

Novel EthR inhibitor, boosting antituberculous activity of ethionamide

Selective delta opioid receptor agonist as a potent and efficacious antihyperalgesic agent

Novel Positive Allosteric Modulator of the α7 Nicotinic Acetylcholine Receptor

Estrogen receptor ESR1 agonist

Vascular endothelial growth factor receptor-2 (VEGF-2) kinase inhibitor

Novel, potent dual inhibitor of the leukocyte proteases cathepsin G and chymase

Novel potent and selective IRAK1 degrader, effectively degraded cellular IRAK1 protein with a DC50 of 3 nM in HBL-1 cells

Novel Potent Human Adenovirus Inhibitor, showing improved anti-HAdV activity (IC50 = 0.27 μM), significantly decreasing cytotoxicity (CC50 = 156.8 μM), and lowering in vivo toxicity (maximum tolerated dose = 150 mg/kg in hamster) as compared with niclosam

Novel Potent NS4B Inhibitor for the Treatment of Dengue Virus Infection

Novel inhibitor of viral protease function, suppressing Zika virus Infection both In vitro and In vivo

Novel partial inverse agonist of GHS-R1a (K i = 3 nM, EC 50 = 70 nM, Emax = −37%)

Novel ghrelin receptor (GHS-R1a) antagonist [IC 50 (affinity): 5 nM IC 50 (Ca ): 60 nM]

Novel potent GHS-R1a agonist (EC50 (Ca ): 1.6 nM), significantly stimulating GH secretion

Potent non-nucleoside inhibitor of HIV-1 reverse transcriptase (NNRTIs)

Novel specific dual inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2) and cyclin-dependent kinase 1 (CDK1), targeting cell cycle progression and angiogenesis

Novel Ras homologous A (RHOA) inhibitor, potently inhibiting cell viability and migration/invasion of gastric cancer (GC) cell lines, and mouse xenografts, diversely expressing RHOA, binding affinity for RHOA was >140-fold greater than Rhosin, a nonclinic

Novel Interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, binding preferentially to unphosphorylated IRAK4

Novel type I Interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, binding preferentially to unphosphorylated IRAK4

Novel inhibitor of the heat shock protein 70 (Hsp70) with anti-proliferative activity in breast and prostate cancer cells

Novel human flap endonuclease 1 (FEN1) inhibitor with in vitro inhibition of flap cleavage activity as well as cytotoxic activity against a colon cancer cell line, DLD-1